Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3313–3336 of 22,009 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Prostate Cancer
Interventions: ADT, ARSI, No ADT/ARSI -decline; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
Interventions: COMP360 psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 14 more

Conditions: Total Knee Arthroplasty, Prosthetic-joint Infection, Irrigation
Interventions: Methylene Blue 10 MG/ML (intra-articular application), Revision Arthroplasty for PJI (DAIR), Primary Total Knee Arthroplasty; Drug · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Device Related Thrombosis, Peri-device Leak
Interventions: Transesophageal echocardiography (TEE), Cardiac CTA; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Roslyn, New York • Charlotte, North Carolina + 2 more

Conditions: Skin Toxicity
Interventions: Complementary and alternative medicine (CAM); Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Interventions: ReCharge, TakeCharge; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Interventions: Intismeran autogene, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more

Conditions: Surgical Drain
Interventions: K-Lock, Suture; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Brain Metastases, HR+ Metastatic Breast Cancer
Interventions: Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Columbus, Ohio

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma (SCC) of the Oral Cavity
Interventions: Reflectance Confocal Microscopy; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 2 more

Conditions: Obesity, Overweight
Interventions: EndoZip System, OverStitch Endoscopic Suturing System (ESG); Device
Lead sponsor: Nitinotes Surgical Ltd.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Orlando, Florida • New York, New York

Conditions: Substance Use Treatment, Perinatal Substance Use, Parenting
Interventions: Proud of Baby and Me; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Localized Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Discussion, Exercise Intervention, Interview, Medical Device Usage and Evaluation, Physical Examination, Physical Performance Testing, Questionnaire Administration, Recreational Therapy; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years to 85 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Insomnia
Interventions: Light Exposure, Placebo; Other
Lead sponsor: Northwestern University; Other
Eligibility: 55 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Topotecan, Lurbinectedin, Amrubicin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 32 more

Conditions: SARS CoV-2 Post-Acute Sequelae
Interventions: DPA-714 PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Drain Output After Breast Reduction Surgery, Breast Reductions
Interventions: IV TXA, Topical TXA, Topical saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cerebral Autosomal Dominant Ateriopathy With Subcortical Infarcts and Leukoencephalopathy
Interventions: Registry; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Relapsed/Refractory B-cell Malignancies
Interventions: AC676; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • Sarasota, Florida • Chapel Hill, North Carolina + 6 more

Conditions: Narcolepsy Type 1 (NT1)
Interventions: VX-433, Placebo, Midazolam, Bupropion; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Interventions: PAS-004 Capsules, PAS-004 Tablets; Drug
Lead sponsor: Pasithea Therapeutics Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas • Fairfax, Virginia

Conditions: Rhinovirus Infection
Interventions: VPV 1000 mg, VPV 500 mg, Placebo; Drug · Other
Lead sponsor: Altesa Biosciences, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more

Conditions: Alzheimer Disease
Interventions: Transcranial direct current stimulation (tDCS), Sham tDCS; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 60 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Depression
Interventions: Guided Mindfulness Practice using a study created web app that links to the commercially available Waking Up app; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Charleston, South Carolina

Search by objective public record fields.

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Methylene Blue in Total Knee Arthroplasty (TKA)

Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Evaluating the Effect of Surgical Drain Securement on Patient Quality of Life and Postoperative Drain-related Complications

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology

Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment

Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors

Noradrenergic Dysregulation, Sleep and Cognition in Older Adults With Insomnia

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

Registry for CADASIL

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

A Phase 1, First-in-human Study of VX-433

PAS-004 in Patients With Advanced Solid Tumors

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms

Mindfulness Training During Accelerated TMS for Depression